Oncologic Drugs Advisory Committee
Purpose
The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate recommendations to the Commissioner of Food and Drugs.
Meeting Information
- 2008 Meetings
- Past Meetings:
Contact
LT Nicole Vesely, Pharm.D., R.Ph., Designated Federal Official
Advisors and Consultants Staff
Center for Drug Evaluation and Research
Food and Drug Administration,
5630 Fishers Lane, HFD-21
Rockville, Maryland 20857
(301) 827-7001
Fax: (301) 827-6776
E-mail: Nicole.Vesely@fda.hhs.gov
Committee Membership
The Committee shall consist of a core of 13 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of general oncology, pediatric oncology, hematologic oncology, immunologic oncology, biostatistics, and other related professions. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.
Committee Resources
- Committee Vacancies
- Committee Charter
- Roster (members)
- FDA Advisory Committee Information Line
1-800-741-8138
(301) 443-0572 (local number)
code: 3014512542
Please call the Information Line for up-to-date information on meetings.
Related Links
Back to Top
Back to Human Drug Advisory Committees
PDF requires the free
Adobe Acrobat Reader
Date created: September 2, 2008; Updated: November 21, 2008 |